Such findings propose that the suppression of SHP2 within tumor tissues may be a stratagem through which G-CSF endorses the initiation of the PI3K/AKT/mTOR pathway, a critical hallmark in the advancement of liver cancer. The gene discussed is CSF3; the disease is liver cancer.